Refractory Multiple Myeloma Clinical Trials

96 recruitingLast updated: July 16, 2026

There are 96 actively recruiting refractory multiple myeloma clinical trials across 39 countries. Studies span Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1. Top locations include Boston, Massachusetts, United States, New York, New York, United States, Atlanta, Georgia, United States. Updated daily from ClinicalTrials.gov.


Refractory Multiple Myeloma Trials at a Glance

96 actively recruiting trials for refractory multiple myeloma are listed on ClinicalTrialsFinder across 6 cities in 39 countries. The largest study group is Phase 1 with 52 trials, with the heaviest enrollment activity in Boston, New York, and Atlanta. Lead sponsors running refractory multiple myeloma studies include Massachusetts General Hospital, Regeneron Pharmaceuticals, and Mayo Clinic.

Browse refractory multiple myeloma trials by phase

Treatments under study

About Refractory Multiple Myeloma Clinical Trials

Looking for clinical trials for Refractory Multiple Myeloma? There are currently 31 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Refractory Multiple Myeloma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Refractory Multiple Myeloma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 96 trials

Recruiting
Phase 2

Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma

Refractory Multiple MyelomaRecurrent Multiple Myeloma
Mayo Clinic62 enrolled1 locationNCT05847569
Recruiting
Phase 3

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Relapsed or Refractory Multiple Myeloma
Celgene810 enrolled266 locationsNCT05519085
Recruiting
Phase 3

A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients

Relapsed/Refractory Multiple Myeloma
Hangzhou Sumgen Biotech Co., Ltd.360 enrolled12 locationsNCT06508983
Recruiting
Phase 1Phase 2

To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma
Hangzhou Sumgen Biotech Co., Ltd.40 enrolled4 locationsNCT07454187
Recruiting
Phase 1Phase 2

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

Relapsed/Refractory Multiple Myeloma
BeOne Medicines246 enrolled84 locationsNCT04973605
Recruiting
Phase 1Phase 2

A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma

Relapsed Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals150 enrolled5 locationsNCT07455851
Recruiting
Phase 2

Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma

Cytokine Release SyndromeRefractory Multiple MyelomaRecurrent Multiple Myeloma
Naresh Bumma35 enrolled1 locationNCT07657312
Recruiting

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

Relapsed Refractory Multiple Myeloma (RRMM)
Janssen-Cilag Ltd.900 enrolled68 locationsNCT06285318
Recruiting

A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma
Janssen Pharmaceutica N.V., Belgium300 enrolled90 locationsNCT05160584
Recruiting
Phase 1

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Relapsed or Refractory Multiple MyelomaPreviously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC180 enrolled29 locationsNCT05652335
Recruiting
Phase 1

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Relapsed or Refractory Multiple Myeloma
Genentech, Inc.120 enrolled14 locationsNCT05927571
Recruiting
Phase 1Phase 2

Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma

Refractory Multiple MyelomaRecurrent Multiple Myeloma
Alliance for Clinical Trials in Oncology88 enrolled42 locationsNCT06232044
Recruiting
Phase 2

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Multiple MyelomaRelapsed/Refractory Multiple Myeloma
C4 Therapeutics, Inc.100 enrolled10 locationsNCT07284758
Recruiting
Phase 3

A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Relapsed and/or Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals915 enrolled20 locationsNCT07222761
Recruiting
Phase 3

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

Relapsed/Refractory Multiple Myeloma
AstraZeneca508 enrolled138 locationsNCT07391657
Recruiting
Phase 2

18F-Fluciclovine PET/CT in Multiple Myeloma

Multiple MyelomaNewly Diagnosed Multiple Myeloma (NDMM)Relapsed and/or Refractory Multiple Myeloma (RRMM)
National Cancer Institute (NCI)60 enrolled1 locationNCT06103838
Recruiting
Phase 1

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

Refractory Multiple MyelomaRecurrent Multiple Myeloma
National Cancer Institute (NCI)26 enrolled14 locationsNCT06465316
Recruiting
Phase 1Phase 2

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma
ModernaTX, Inc.166 enrolled10 locationsNCT07116616
Recruiting
Phase 3

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Relapsed or Refractory Multiple Myeloma (RRMM)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company440 enrolled140 locationsNCT06615479
Recruiting
Phase 1Phase 2

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

Relapsed/Refractory Multiple Myeloma
AstraZeneca182 enrolled36 locationsNCT05850234